Maze Therapeutics Surges 60% After $150M Raise and Shionogi License Amid Regulatory Scrutiny
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Maze Therapeutics Inc (NASDAQ: MAZE) is a South San Francisco–based clinical-stage biopharmaceutical company founded in 2018. The firm utilizes insights from human genetics through its Compass platform to develop small molecule precision medicines targeting renal, cardiovascular, and related metabolic disorders. Its lead programs focus on APOL1-mediated kidney disease (MZE829) and phenylketonuria (MZE782), with additional candidates in preclinical stages.
Corporate Structure
Maze employs between 51 and 200 professionals across research, development, and corporate functions. In August 2025, Misbah Tahir was appointed as chief financial officer, bringing over 20 years of financial and strategic experience in the biopharmaceutical industry. The company’s governance includes external investors such as Frazier Life Sciences Public Fund, L.P., which reported beneficial ownership of 3,352,915 shares, representing 7.7% of the outstanding stock, as of its August 14, 2025 Schedule 13G/A amendment.
Biopharmaceuticals by little plant
Recent Developments and News
- December 13, 2023: The Federal Trade Commission moved to dismiss its antitrust challenge following Sanofi’s termination of a planned transaction with Maze Therapeutics.
- May 10, 2024: Maze and Shionogi & Co., Ltd. executed an exclusive worldwide license agreement for MZE001, an investigational oral GYS1 inhibitor for Pompe disease.
- Mid-2024: After Vertex Pharmaceuticals raised a promotional claims challenge to the National Advertising Division (NAD) regarding MZE829, Maze declined to participate, leading the NAD to refer the matter to federal regulators for review.
- June 30, 2025: The company reported second-quarter financial results, highlighting pipeline progress and anticipated clinical milestones.
- 2025 (LinkedIn announcement): Maze completed an oversubscribed private placement of $150 million to support its small molecule pipeline.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Stock Price (USD) | 25.65 |
| Change (%) | +60.11% |
| Volume | 279,627 |
| Exchange | NASDAQ |
| Ticker | MAZE |
The September 11, 2025 closing price of $25.65 reflects a 60.11% year-to-date increase. The $150 million private placement enhances the balance sheet, funding ongoing Phase 2 trials for MZE829 and studies for MZE782. The collaboration with Shionogi diversifies the pipeline into lysosomal storage disorders. Ownership by specialized life sciences funds indicates interest in the precision medicine strategy.
Market Position and Industry Context
Operating in the biotechnology research sector, Maze competes with established and emerging companies in genetic-driven therapeutics. Its focus on small molecules differs from the biologics and gene therapy approaches utilized by some competitors. Regulatory interactions—such as the FTC dismissal and the NAD referral—underscore the scrutiny pharmaceutical companies face in marketing and merger activities. Strategic partnerships and a focused pipeline position Maze to address needs in kidney and metabolic diseases.
tl;dr
On September 11, 2025, MAZE shares closed at $25.65, up 60.11% year-to-date. The company secured $150 million in a private placement, reported Q2 pipeline advancements as of June 30, 2025, and advanced MZE829 into Phase 2. A May 10, 2024 license with Shionogi extends its reach into Pompe disease, while a Vertex-initiated NAD challenge was referred to federal regulators. Future milestones include Phase 1 data for MZE782 and regulatory reviews of promotional practices.